{
    "clinical_study": {
        "@rank": "141241", 
        "arm_group": [
            {
                "arm_group_label": "Trabodenoson Plus Latanoprost", 
                "arm_group_type": "Experimental", 
                "description": "Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop"
            }, 
            {
                "arm_group_label": "Timolol Plus Latanoprost", 
                "arm_group_type": "Active Comparator", 
                "description": "A Beta-blocker eye drop plus a prostaglandin analogue eye drop"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the intraocular pressure (IOP) lowering efficacy\n      and the safety and tolerability profile of trabodenoson ophthalmic formulation compared to\n      timolol maleate ophthalmic solution 0.5% in adults with ocular hypertension (OHT) or primary\n      open-angle glaucoma (POAG) who are already receiving treatment with latanoprost ophthalmic\n      solution 0.005% once every evening (QPM)."
        }, 
        "brief_title": "A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Open-Angle Glaucoma (POAG) and Ocular Hypertension (OHT)", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "Criteria\n\n      Inclusion Criteria:\n\n        1. Subject has signed and dated the current informed consent form (ICF).\n\n        2. Subject has the diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma\n           (POAG) (excluding secondary, pseudo-exfoliation, and pigment dispersion glaucomas).\n\n        3. Aged 18 or older.\n\n        4. Mean intraocular pressure (IOP) of \u226524 and \u226434 mm Hg.\n\n      Exclusion Criteria:\n\n        1. No significant visual field loss or any new field loss within the past year.\n\n        2. Cup-to-disc ratio \u22650.8\n\n        3. Central corneal thickness <500 \u00b5m or >600 \u00b5m\n\n        4. A recent (acute) or chronic medical condition that might obfuscate the Subject's study\n           data"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject has signed and dated the current informed consent form (ICF).\n\n          2. Subject has the diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma\n             (POAG) (excluding secondary, pseudo-exfoliation, and pigment dispersion glaucomas).\n\n          3. Aged 18 or older.\n\n          4. Mean intraocular pressure (IOP) of \u226524 and \u226434 mm Hg.\n\n        Exclusion Criteria:\n\n          1. No significant visual field loss or any new field loss within the past year.\n\n          2. Cup-to-disc ratio \u22650.8\n\n          3. Central corneal thickness <500 \u00b5m or >600 \u00b5m\n\n          4. A recent (acute) or chronic medical condition that might obfuscate the Subject's\n             study data"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917383", 
            "org_study_id": "IPC-01-2013"
        }, 
        "intervention": {
            "arm_group_label": [
                "Trabodenoson Plus Latanoprost", 
                "Timolol Plus Latanoprost"
            ], 
            "description": "Ophthalmic eye drop", 
            "intervention_name": "Trabodenoson", 
            "intervention_type": "Drug", 
            "other_name": "INO-8875"
        }, 
        "intervention_browse": {
            "mesh_term": "Latanoprost"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "glaucoma", 
            "primary open angle glaucoma", 
            "ocular hypertension", 
            "adenosine agonist", 
            "eye drop", 
            "trabodenoson", 
            "trabecular meshwork"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "location": {
            "contact": {
                "email": "Janet.Combs@chiltern.com", 
                "last_name": "Janet Combs, BS", 
                "phone": "423-990-0361"
            }, 
            "facility": {
                "address": {
                    "city": "Bristol", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37620"
                }, 
                "name": "Chiltern"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma", 
        "overall_contact": {
            "last_name": "Janet Combs", 
            "phone": "423-968-9533"
        }, 
        "overall_contact_backup": {
            "last_name": "Audrey Rossow, BA", 
            "phone": "508-808-5489"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Intraocular Pressure (IOP)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917383"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Inotek Pharmaceuticals Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Inotek Pharmaceuticals Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}